185 related articles for article (PubMed ID: 28135068)
1. Development of Potent, Selective SRPK1 Inhibitors as Potential Topical Therapeutics for Neovascular Eye Disease.
Batson J; Toop HD; Redondo C; Babaei-Jadidi R; Chaikuad A; Wearmouth SF; Gibbons B; Allen C; Tallant C; Zhang J; Du C; Hancox JC; Hawtrey T; Da Rocha J; Griffith R; Knapp S; Bates DO; Morris JC
ACS Chem Biol; 2017 Mar; 12(3):825-832. PubMed ID: 28135068
[TBL] [Abstract][Full Text] [Related]
2. Topical antiangiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative AMD.
Gammons MV; Fedorov O; Ivison D; Du C; Clark T; Hopkins C; Hagiwara M; Dick AD; Cox R; Harper SJ; Hancox JC; Knapp S; Bates DO
Invest Ophthalmol Vis Sci; 2013 Sep; 54(9):6052-62. PubMed ID: 23887803
[TBL] [Abstract][Full Text] [Related]
3. Altered VEGF Splicing Isoform Balance in Tumor Endothelium Involves Activation of Splicing Factors Srpk1 and Srsf1 by the Wilms' Tumor Suppressor Wt1.
Wagner KD; El Maï M; Ladomery M; Belali T; Leccia N; Michiels JF; Wagner N
Cells; 2019 Jan; 8(1):. PubMed ID: 30641926
[TBL] [Abstract][Full Text] [Related]
4. Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer.
Mavrou A; Brakspear K; Hamdollah-Zadeh M; Damodaran G; Babaei-Jadidi R; Oxley J; Gillatt DA; Ladomery MR; Harper SJ; Bates DO; Oltean S
Oncogene; 2015 Aug; 34(33):4311-9. PubMed ID: 25381816
[TBL] [Abstract][Full Text] [Related]
5. Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis.
Nowak DG; Amin EM; Rennel ES; Hoareau-Aveilla C; Gammons M; Damodoran G; Hagiwara M; Harper SJ; Woolard J; Ladomery MR; Bates DO
J Biol Chem; 2010 Feb; 285(8):5532-40. PubMed ID: 19906640
[TBL] [Abstract][Full Text] [Related]
6. Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma.
Gammons MV; Lucas R; Dean R; Coupland SE; Oltean S; Bates DO
Br J Cancer; 2014 Jul; 111(3):477-85. PubMed ID: 25010863
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of serine/arginine-rich protein kinase-1 (SRPK1) prevents cholangiocarcinoma cells induced angiogenesis.
Supradit K; Boonsri B; Duangdara J; Thitiphatphuvanon T; Suriyonplengsaeng C; Kangsamaksin T; Janvilisri T; Tohtong R; Yacqub-Usman K; Grabowska AM; Bates DO; Wongprasert K
Toxicol In Vitro; 2022 Aug; 82():105385. PubMed ID: 35568131
[TBL] [Abstract][Full Text] [Related]
8. WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing.
Amin EM; Oltean S; Hua J; Gammons MV; Hamdollah-Zadeh M; Welsh GI; Cheung MK; Ni L; Kase S; Rennel ES; Symonds KE; Nowak DG; Royer-Pokora B; Saleem MA; Hagiwara M; Schumacher VA; Harper SJ; Hinton DR; Bates DO; Ladomery MR
Cancer Cell; 2011 Dec; 20(6):768-80. PubMed ID: 22172722
[TBL] [Abstract][Full Text] [Related]
9. SRPK1 inhibition in vivo: modulation of VEGF splicing and potential treatment for multiple diseases.
Oltean S; Gammons M; Hulse R; Hamdollah-Zadeh M; Mavrou A; Donaldson L; Salmon AH; Harper SJ; Ladomery MR; Bates DO
Biochem Soc Trans; 2012 Aug; 40(4):831-5. PubMed ID: 22817743
[TBL] [Abstract][Full Text] [Related]
10. Serine-arginine-rich protein kinase-1 inhibition for the treatment of diabetic retinopathy.
Malhi NK; Allen CL; Stewart E; Horton KL; Riu F; Batson J; Amoaku W; Morris JC; Arkill KP; Bates DO
Am J Physiol Heart Circ Physiol; 2022 Jun; 322(6):H1014-H1027. PubMed ID: 35302878
[TBL] [Abstract][Full Text] [Related]
11. SRPKIN-1: A Covalent SRPK1/2 Inhibitor that Potently Converts VEGF from Pro-angiogenic to Anti-angiogenic Isoform.
Hatcher JM; Wu G; Zeng C; Zhu J; Meng F; Patel S; Wang W; Ficarro SB; Leggett AL; Powell CE; Marto JA; Zhang K; Ki Ngo JC; Fu XD; Zhang T; Gray NS
Cell Chem Biol; 2018 Apr; 25(4):460-470.e6. PubMed ID: 29478907
[TBL] [Abstract][Full Text] [Related]
12. Identification of a Dual Inhibitor of SRPK1 and CK2 That Attenuates Pathological Angiogenesis of Macular Degeneration in Mice.
Morooka S; Hoshina M; Kii I; Okabe T; Kojima H; Inoue N; Okuno Y; Denawa M; Yoshida S; Fukuhara J; Ninomiya K; Ikura T; Furuya T; Nagano T; Noda K; Ishida S; Hosoya T; Ito N; Yoshimura N; Hagiwara M
Mol Pharmacol; 2015 Aug; 88(2):316-25. PubMed ID: 25993998
[TBL] [Abstract][Full Text] [Related]
13. Targeting alternative splicing as a new cancer immunotherapy-phosphorylation of serine arginine-rich splicing factor (SRSF1) by SR protein kinase 1 (SRPK1) regulates alternative splicing of PD1 to generate a soluble antagonistic isoform that prevents T cell exhaustion.
Wahid M; Pratoomthai B; Egbuniwe IU; Evans HR; Babaei-Jadidi R; Amartey JO; Erdelyi V; Yacqub-Usman K; Jackson AM; Morris JC; Patel PM; Bates DO
Cancer Immunol Immunother; 2023 Dec; 72(12):4001-4014. PubMed ID: 37973660
[TBL] [Abstract][Full Text] [Related]
14. WT1 activates transcription of the splice factor kinase SRPK1 gene in PC3 and K562 cancer cells in the absence of corepressor BASP1.
Belali T; Wodi C; Clark B; Cheung MK; Craig TJ; Wheway G; Wagner N; Wagner KD; Roberts S; Porazinski S; Ladomery M
Biochim Biophys Acta Gene Regul Mech; 2020 Dec; 1863(12):194642. PubMed ID: 33017668
[TBL] [Abstract][Full Text] [Related]
15. The control of alternative splicing by SRSF1 in myelinated afferents contributes to the development of neuropathic pain.
Hulse RP; Drake RA; Bates DO; Donaldson LF
Neurobiol Dis; 2016 Dec; 96():186-200. PubMed ID: 27616424
[TBL] [Abstract][Full Text] [Related]
16. Identification of a novel and potent small molecule inhibitor of SRPK1: mechanism of dual inhibition of SRPK1 for the inhibition of cancer progression.
Chandra A; Ananda H; Singh N; Qamar I
Aging (Albany NY); 2020 Dec; 13(1):163-180. PubMed ID: 33291073
[TBL] [Abstract][Full Text] [Related]
17. Protein-Protein Interaction Inhibitor of SRPKs Alters the Splicing Isoforms of VEGF and Inhibits Angiogenesis.
Li Q; Zeng C; Liu H; Yung KWY; Chen C; Xie Q; Zhang Y; Wan SWC; Mak BSW; Xia J; Xiong S; Ngo JCK
iScience; 2021 May; 24(5):102423. PubMed ID: 33997701
[TBL] [Abstract][Full Text] [Related]
18. Intra-domain Cross-talk Regulates Serine-arginine Protein Kinase 1-dependent Phosphorylation and Splicing Function of Transformer 2β1.
Jamros MA; Aubol BE; Keshwani MM; Zhang Z; Stamm S; Adams JA
J Biol Chem; 2015 Jul; 290(28):17269-81. PubMed ID: 26013829
[TBL] [Abstract][Full Text] [Related]
19. SRPK1 and Clk/Sty protein kinases show distinct substrate specificities for serine/arginine-rich splicing factors.
Colwill K; Feng LL; Yeakley JM; Gish GD; Cáceres JF; Pawson T; Fu XD
J Biol Chem; 1996 Oct; 271(40):24569-75. PubMed ID: 8798720
[TBL] [Abstract][Full Text] [Related]
20. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors.
Nowak DG; Woolard J; Amin EM; Konopatskaya O; Saleem MA; Churchill AJ; Ladomery MR; Harper SJ; Bates DO
J Cell Sci; 2008 Oct; 121(Pt 20):3487-95. PubMed ID: 18843117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
